Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HutchMed Completes US Filing of Fruquintinib for Metastatic Colorectal Cancer

publication date: Apr 4, 2023

Shanghai HutchMed has completed the rolling submission of a US NDA for its lead drug, fruzuintinib, an oral VEGFR-1, -2 and -3 inhibitor, for patients with refractory metastatic colorectal cancer. A global Phase III trial showed fruquintinib increased overall and progression free survival endpoints compared to best supporting care, while improving tolerability because of its increased kinase selectivity. Fruquintinib was launched in China five years ago with the name Elunate®. In January of this year, HutchMed out-licensed ex-China rights for the drug to Takeda in a deal worth $1.1 billion. More details....

Stock Symbols: (NSDQ/AIM: ​HCM, HKEX:​13)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital